Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer-Reference-Cited by-同舟云学术

Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer

Published:2017-03 Issue:3 Volume:46 Page:335-340
ISSN:0885-3177
Container-title:Pancreas
language:en
Short-container-title:

Author:

Hayashi Hideyuki,Kohno Takashi,Ueno Hideki,Hiraoka Nobuyoshi,Kondo Shunsuke,Saito Motonobu,Shimada Yoko,Ichikawa Hitoshi,Kato Mamoru,Shibata Tatsuhiro,Morizane Chigusa,Sakamoto Yasunari,Shimada Kazuaki,Komatsu Yoshito,Sakamoto Naoya,Okusaka Takuji

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Endocrinology,Hepatology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference29 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

3. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group;Moore;J Clin Oncol,2007

4. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011

5. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study;Ueno;J Clin Oncol,2013

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer;Current Issues in Molecular Biology;2024-03-23

2. Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma;Cancer Science;2024-02-06

3. Successful immunotherapy with PD-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature;Anti-Cancer Drugs;2024-01-08

4. SMAD4 loss predicts worse overall and distant metastasis‐free survival in patients with resected pancreatic adenocarcinoma;Cancer;2023-10-12

5. The role of diagnostic, prognostic, and predictive biomarkers in the management of early pancreatic cancer;Journal of Cancer Research and Clinical Oncology;2023-07-17